MedTrace Logo

Does PTH 1-34 (Teriparatide) Enhance Spinal Fusion in Humans?

NCT02090244 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2019-04-17

No results posted yet for this study

Summary

Parathyroid (PTH) hormone has been shown to enhance fracture healing in animal studies. There are so far only three published papers concerning humans. Postero-lateral fusions have shown a healing rate of less than 50% after bone. The purpose of this study is to determine if PTH 1-34 (teriparatide) improves the healing rate and the clinical course after spinal stenosis surgery.

Conditions

  • Spinal Stenosis

Interventions

DRUG

Teriparatide

Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks

Sponsors & Collaborators

  • Medical Research Council of Southeast Sweden

    collaborator OTHER_GOV

  • University Hospital, Linkoeping

    lead OTHER

Principal Investigators

  • Jon Ottesen, MD · Ryggkliniken, US Linköping

  • Patrik Bernestrå, MD · Ortopedkliniken, Kalmar, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2018-05-31
Completion
2019-01-01

Countries

  • Sweden

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02090244 on ClinicalTrials.gov